期刊
INTERNATIONAL JOURNAL OF CANCER
卷 124, 期 6, 页码 1449-1456出版社
WILEY
DOI: 10.1002/ijc.24080
关键词
CDC25 phosphatase; cell cycle; cancer; pharmacology
类别
资金
- CNRS
- University of Toulouse
- Region Midi-Pyrenees and La Ligue Nationale Centre le Cancer
CDC25 phosphatases are key actors in cycl in-dependent kinases activation whose role is essential at various stages of the cell cycle. CDC25 expression is upregulated in a number of human cancers. CDC25 phosphatases are therefore thought to represent promising novel targets in cancer therapy. Here, we report the identification and the characterization of IRC-083864, an original bis-quinone moiety that is a potent and selective inhibitor of CDC25 phosphatases in the low nanomolar range. IRC-083864 inhibits cell proliferation of a number of cell lines, regardless of their resistance to other drugs. It irreversibly inhibits cell proliferation and cell cycle progression and prevents entry into mitosis. In addition, it inhibits the growth of HCT-116 tumor spheroids with induction of p21 and apoptosis. Finally, IRC-083864 reduced tumor growth in mice with established human prostatic and pancreatic tumor xenografts. This study describes a novel compound, which merits further study as a potential anticancer agent. (C) 2008 Wiley-Liss, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据